Hansen L B, Larsen N E, Gulmann N
Psychopharmacology (Berl). 1982;78(2):112-5. doi: 10.1007/BF00432245.
A group of 26 acute psychotic patients received continuous oral treatment with perphenazine for a period of 5 weeks. Once-weekly blood samples were drawn for measurements of perphenazine levels and, simultaneously, the therapeutic outcome was registered. Another 26 acute psychotic patients received continuous oral treatment with perphenazine for a period of up to 4 weeks. A single blood sample was drawn and the perphenazine concentration was related to the appearance of extrapyramidal side effects. The following conclusions were made: (1) a high risk of provoking extrapyramidal side effects was associated with plasma levels of perphenazine above 3 nmol/l; (2) plasma levels below 2 nmol/l were associated with a poor therapeutic outcome; (3) a 'therapeutic window' between 2 and 3 nmol/l gives maximal therapeutic effect with a low risk of provoking extrapyramidal side effects.
一组26名急性精神病患者接受了为期5周的奋乃静持续口服治疗。每周采集一次血样以测量奋乃静水平，同时记录治疗结果。另外26名急性精神病患者接受了为期最长4周的奋乃静持续口服治疗。采集了一次血样，并将奋乃静浓度与锥体外系副作用的出现情况进行关联。得出了以下结论：（1）血浆奋乃静水平高于3 nmol/l时，引发锥体外系副作用的风险较高；（2）血浆水平低于2 nmol/l与治疗效果不佳有关；（3）2至3 nmol/l之间的“治疗窗”可带来最大治疗效果，且引发锥体外系副作用的风险较低。
